On June 28, 2017, Avadel Pharmaceuticals plc (the “Company“) held its 2017 annual general meeting of shareholders (the “2017 Meeting“). As reported below in Item 5.07 of this current report on Form 8-K, at the 2017 Meeting the shareholders of the Company approved the Avadel Pharmaceuticals plc 2017 Omnibus Incentive Compensation Plan (the “2017 Omnibus Plan“) and the Avadel Pharmaceuticals plc 2017 Employee Share Purchase Plan (the “2017 ESPP“).

A description of the material terms of the 2017 Omnibus Plan is set forth beginning on page 36 of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on May 1, 2017 (the “Proxy Statement“) under the caption “Proposal 3 Approval of the Avadel Pharmaceuticals plc 2017 Omnibus Incentive Compensation Plan”; such description is incorporated herein by reference in its entirety. The complete text of the 2017 Omnibus Plan is incorporated herein as Exhibit 10.1 to this current report on Form 8-K by reference to Annex A to the Proxy Statement.

A description of the material terms of the 2017 ESPP is set forth beginning on page 42 of the Proxy Statement under the caption “Proposal 4 Approval of the Avadel Pharmaceuticals plc 2017 Employee Share Purchase Plan”; such description is incorporated herein by reference in its entirety. The complete text of the 2017 ESPP is incorporated herein as Exhibit 10.2 to this current report on Form 8-K by reference to Annex B to the Proxy Statement.

On June 28, 2017, the Compensation Committee of the Company’s Board of Directors approved the form of Stock Option Agreement attached hereto as Exhibit 10.3 for use in connection with awards of employee stock options under the 2017 Omnibus Plan, and such form is incorporated by reference herein.

Item 5.07 Submission of Matters to a vote of Security Holders.

Results of Shareholders Votes at the 2017 Meeting. The final voting results on each of the matters submitted to a vote of security holders at the 2017 Meeting are set forth below. There were 41,384,854 ordinary shares issued and outstanding at 5:00pm (Irish Standard Time) on May 19, 2017 and entitled to vote at the 2017 Meeting. A total of 40,549,866 ordinary shares (97.98%) were represented at the 2017 Meeting.

(i) Resolution 1. The shareholders approved each of the six director nominees for one-year terms expiring at the 2018 annual general meeting of shareholders. The results of the shareholders’ vote with respect to each director nominee were as follows:

For		Against		Abstentions
40,488,168		25,584		36,144

For		Against		Abstentions
39,351,239		1,151,486		47,141

For		Against		Abstentions
39,668,984		837,443		43,439